J&J devices & diagnostics grow faster than pharmaceutical
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's 11% first-quarter group sales growth - to $12.8bn - was driven by a 16% increase in revenues from devices and diagnostics, to $4.8bn. The company's larger pharmaceutical business posted a more modest increase of 7%, to $5.8bn, while consumer sales were up 11%.